ClinicalTrialsFinder

KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC) Clinical Trials in Philadelphia, Pennsylvania

1 recruitingPhiladelphia, Pennsylvania

Showing 1–1 of 1 trials

Recruiting
Phase 1

A Phase 1 Dose-escalation Trial of KST-6051 in Participants With Advanced Solid Tumors With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) Mutation

KRAS-mutant Non-small Cell Lung Cancer (NSCLC)KRAS-mutant Pancreatic Ductal Adenocarcinoma (PDAC)KRAS-mutant Colorectal Cancer (CRC)+1 more
Kestrel Therapeutics, Inc.145 enrolled5 locationsNCT07458347